Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies
Open Access
- 1 January 2021
- journal article
- research article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (1) , 216-224.e1
Abstract
No abstract availableKeywords
Funding Information
- Aimmune Therapeutics
- Genentech
- National Peanut Board
- Johnson and Johnson
- Allergy Therapeutics
- Merck
- European Academy of Allergy and Clinical Immunology
- Sanofi Genzyme
- National Children's Research Centre
- Agency for Healthcare Research and Quality (5K08HS024599-02)
- National Institute of Allergy and Infectious Diseases
This publication has 28 references indexed in Scilit:
- The Public Health Impact of Parent-Reported Childhood Food Allergies in the United StatesPediatrics, 2018
- Allergen-Specific Immunotherapies for Food AllergyAllergy, Asthma & Immunology Research, 2018
- EAACI Guidelines on allergen immunotherapy: IgE‐mediated food allergyAllergy, 2017
- An update on the impact of food allergy on anxiety and quality of lifeCurrent Opinion in Pediatrics, 2017
- The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: HealthNuts age 4-year follow-upJournal of Allergy and Clinical Immunology, 2017
- Quality of life in childhood, adolescence and adult food allergy: Patient and parent perspectivesClinical & Experimental Allergy, 2016
- Emergency and Hospital Care for Food-Related Anaphylaxis in ChildrenHospital Pediatrics, 2016
- Food allergy: A practice parameter update—2014Journal of Allergy and Clinical Immunology, 2014
- Prevalence of common food allergies in Europe: a systematic review and meta-analysisAllergy, 2014
- Assessment of quality of life in children with peanut allergyPediatric Allergy and Immunology, 2003